LRBA Inhibitors
LRBA inhibitors belong to a class of chemical compounds specifically designed to target and modulate the activity of the LRBA protein, also known as LPS-responsive beige-like anchor protein. LRBA is a multi-domain protein that plays essential roles in various cellular processes, particularly in the regulation of immune responses and the maintenance of immune cell homeostasis. It is implicated in processes such as intracellular vesicle trafficking, protein sorting, and autophagy, all of which are critical for the proper functioning of the immune system. Inhibitors designed to target LRBA are primarily employed in molecular and cellular biology research to investigate the functional properties and regulatory mechanisms associated with this protein.
The development of LRBA inhibitors typically involves a combination of biochemical, biophysical, and structural approaches aimed at identifying or designing molecules that can selectively interact with LRBA and modulate its activity within immune cells and other cellular contexts. By inhibiting LRBA, these compounds can potentially disrupt its functions in regulating intracellular vesicle trafficking, autophagy, and immune signaling pathways, thereby affecting immune cell function and immune system homeostasis. Researchers use LRBA inhibitors to explore the intricate roles played by this protein in cellular processes, attempting to unravel its contributions to immune responses, antibody production, and immune cell differentiation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that is part of signaling pathways that could regulate LRBA expression. | ||||||
WYE-354 | 1062169-56-5 | sc-364652 sc-364652A | 10 mg 50 mg | $286.00 $1200.00 | ||
WYE-354 is an mTOR inhibitor that could indirectly reduce LRBA expression by modulating mTOR-dependent signaling pathways. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is another mTOR inhibitor, which might downregulate LRBA expression through the mTOR signaling pathway. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective inhibitor of mTOR kinase activity, potentially affecting LRBA expression. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
This compound is an mTOR inhibitor that might modulate expression of proteins regulated by the mTOR pathway, such as LRBA. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
As an mTOR inhibitor, AZD8055 could influence LRBA expression by altering mTOR signaling. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $321.00 $1835.00 | ||
MLN0128 is a potent mTOR inhibitor that could indirectly decrease LRBA expression by affecting upstream signaling. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
P529 inhibits the AKT/mTOR pathway, which might result in lowered LRBA expression. | ||||||
OSI-027 | 936890-98-1 | sc-364557 sc-364557A | 10 mg 50 mg | $437.00 $1186.00 | 1 | |
OSI-027 is an mTOR inhibitor that could potentially reduce the expression of LRBA by modulating mTOR-related signaling. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus specifically targets mTORC1, which could affect the expression of downstream proteins including LRBA. | ||||||